Stockscreener 앱 받기
67.97
0.38%
-0.30
전일 마감가:
$68.27
열려 있는:
$68.47
하루 거래량:
292.36K
Relative Volume:
0.14
시가총액:
$13.56B
수익:
$4.41B
순이익/손실:
$21.27M
주가수익비율:
212.41
EPS:
0.32
순현금흐름:
$288.81M
1주 성능:
+0.38%
1개월 성능:
+4.15%
6개월 성능:
-1.21%
1년 성능:
+9.06%
1일 변동 폭
$67.86
$69.19
1주일 범위
$67.86
$71.29
52주 변동 폭
$53.56
$83.95
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
67.97 | 13.56B | 4.41B | 21.27M | 288.81M | 0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.42 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
507.38 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.41 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.72 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte (INCY) Secures FDA Approval for Monjuvi in Follicular Lym - GuruFocus
Incyte wins FDA label expansion for lymphoma drug Monjuvi (INCY) - Seeking Alpha
FDA Approves Incyte's Monjuvi for Follicular Lymphoma Treatment | INCY Stock News - GuruFocus
FDA approves Monjuvi combination therapy for follicular lymphoma By Investing.com - Investing.com Canada
FDA Approves Incyte's (INCY) Tafasitamab-Cxix for Follicular Lym - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in - GuruFocus
Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | I - GuruFocus
Incyte (INCY) Surges on Promising Blood Disorder Treatment Results - GuruFocus
Alopecia Areata Market Expected to Experience Major Growth - openPR.com
QGEN Stock Rises in After Market Following Partnership With Incyte - Yahoo Finance
Incyte stock rating reiterated by Oppenheimer on promising cancer drug data - Investing.com Canada
Jefferies raises Incyte stock price target on promising drug data By Investing.com - Investing.com Canada
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses - Benzinga
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms - Yahoo Finance
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Jefferies raises Incyte stock price target on promising drug data - Investing.com
Incyte (INCY) Receives Upgrade Amid Promising Drug Data | INCY Stock News - GuruFocus
Incyte stock rating upgraded by Stifel on promising blood disorder drug - Investing.com
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 - BioSpace
Incyte (INCY) Reports Promising Results for Novel Antibody in My - GuruFocus
Incyte (INCY) Receives Upgrade to Buy with $107 Price Target | INCY Stock News - GuruFocus
Incyte (INCY) Reports Promising Results for Novel Antibody in Myeloproliferative Neoplasms | INCY Stock News - GuruFocus
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers - Nasdaq
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches - Insider Monkey
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Quantisnow
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR- - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma – Company AnnouncementFT.com - Financial Times
Incyte’s SWOT analysis: stock faces patent cliff as pipeline progress mixed - Investing.com
Specialised Therapeutics announces expanded partnership with Incyte - Yahoo Finance
Specialised Therapeutics Expands Partnership with Incyte to Incl - GuruFocus
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - BioSpace
Incyte (INCY) Reports Promising Results from Phase 3 Retifanlimab Trial | INCY Stock News - GuruFocus
Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with - GuruFocus
) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - Business Wire
Specialised Therapeutics expands oncology portfolio with Incyte deal - Investing.com
Incyte (INCY) Expands Partnership with Specialised Therapeutics in Asia-Pacific | INCY Stock News - GuruFocus
Incyte Doubles Down in Asia-Pacific: New Partnership Brings Breakthrough Cancer Treatments to High-Need Markets - Stock Titan
Incyte Corporation (INCY) Announces Amendments to Stock Incentiv - GuruFocus
Incyte stockholders endorse plan amendments and board members By Investing.com - Investing.com Canada
Incyte stockholders endorse plan amendments and board members - Investing.com
Incyte stock holds steady as UBS maintains neutral rating - Investing.com
Incyte to Showcase Groundbreaking Hematology/Oncology Data at EHA 2025 - MSN
Incyte at Goldman Sachs Conference: Growth Beyond Jakafi - Investing.com
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo
Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech
Morgan Stanley Maintains Hold Rating on Incyte (INCY) Stock - Insider Monkey
Stifel maintains hold rating on Incyte stock, keeps $75 price target - Investing.com
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
인사이트 코퍼레이션 주식 (INCY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Jun 03 '25 |
Sale |
68.00 |
1,795 |
122,060 |
26,504 |
0.79%
0.99%
자본화:
|
볼륨(24시간):